drugset / Trial / NCT01115036
A Panobinostat Presurgery
Non-randomizedSingle-groupOpen-labelTreatment
Summary
In the current study, the investigators will evaluate intratumoral pharmacodynamic and pharmacokinetic data associated with the administration of the HDACI, Panobinostat, among recurrent GBM patients. In addition, this study will evaluate the safety and tolerability of this agent, as well as evidence of anti-tumor activity in the patient population.
Timeline
- Start
- 2010-04
- Primary completion
- 2011-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Panobinostat | Small molecule | 20 mg | Oral |